Pharmacology and efficacy of cyclooxygenase (COX) inhibitors

American Journal of Medicine

Volumn 107, Issue 6 SUPPL. 1, 1999, Pages 18-22

  Furst, Daniel E ^a  

^a BENAROYA RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; DICLOFENAC; ETODOLAC; FLURBIPROFEN; IBUPROFEN; INDOMETACIN; MELOXICAM; NABUMETONE; NAPROXEN; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; PROSTAGLANDIN SYNTHASE INHIBITOR; ROFECOXIB;

ANTIINFLAMMATORY ACTIVITY; BIOEQUIVALENCE; CONFERENCE PAPER; DOSE RESPONSE; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG TOXICITY; ENZYME INHIBITION; GASTROINTESTINAL HEMORRHAGE; HUMAN; IN VITRO STUDY; LIPOPHILICITY; NONHUMAN; PEPTIC ULCER; PKA; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

EID: 0033451654     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0002-9343(99)00364-2     Document Type: Conference Paper

References (25)

1. Pairet M, van Ryan J, Schierok H, et al. Differential inhibition of cyclo-oxygenase-1 and -2 by meloxicam and its 4′ isomer. Inflamm Res. 1998;47:270-276.
2. Vane JR, Bakhle YS, Botting RM. Cyclooxygenase 1 and 2. Annu Rev Pharmacol Toxicol. 1998;18:97-120.
3. Dvornik DM. Tissue selective inhibition of prostaglandin biosynthesis by etodolac. J Rheumatol Suppl. 1997;24:40-47.
4. Adams I, Neuman RG, Sachs J, Bralow SP. Efficacy and gastric safety of etodolac as determined in cultured human gastric and synovial cells. Gastroenterology. 1990(suppl): 98:A14. (Abstr.)
5. Patrignani P, Panara MR, Greco A, et al. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthesis. J Pharmacol Exp Ther. 1994;271:1705-1712.
6. 2 production. Inflamm Res. 1996;45:246-253.
7. Rabasseda X. Nimesulide: a selective cyclooxygenase 2 inhibitor anti-inflammatory drug. Drugs Today. 1996; 32(suppl D):1-23.
8. Fenner H. Differentiating among nonsteroidal anti-inflammatory drugs by pharmacokinetic and pharmacodynamic profiles. Semin Arthritis Rheum. 1997;26(suppl 6):28-33.
9. Davis R, Brogden RN. Nimesulide. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy. Drugs. 1994;48:431-454.
10. Turck D, Busch U, Heinzel G, Narjes H. Clinical pharmacokinetics of meloxicam. Arzneimittelforschung/Drug Res. 1997;47:253-258.
11. Wallis WJ, Sunken PA. Antirheumatic drug concentrations in human synovial fluid and synovial tissue. Observations in extravascular pharmacokinetics. Clin Pharmacokinet. 1983; 8:496-522.
12. Furst DE, Hillson JL. What is the role of selective COX-2 inhibitors in the spectrum of NSAID therapy. Rheum Grand Rounds. 1998;1:1-10.
13. Wallace JL Selective COX-2 inhibitors: is the water becoming muddy? TIPS. 1999;20:4-6.
14. Amin AR, Vyas P, Attur M, et al. The mode of action of aspirin-like drugs: effect on inducible NOS. Proc Natl Acad Sci USA. 1995;92:7926-7930.
15. th ed. Baltimore: Williams & Wilkins; 1996:611-654.
16. Heller CA, Ingelfinger JA, Goldman P. Nonsteroidal anti-inflammatory drugs and aspirin - analyzing the scores. Pharmacotherapy. 1985;5:30-38.
17. Neustadt DH. Double-blind evaluation of the long-term effects of etodolac vs ibuprofen in patients with rheumatoid arthritis. J Rheumatol Suppl. 1997;24:17-22.
18. Schnitzer TJ, Constantine G. Etodolac (Lodine) in the treatment of osteoarthritis: recent studies. J Rheumatol Suppl. 1997;24:23-31.
19. Furst DE. Meloxicam: selective COX-2 inhibition in clinical practice. Semin Arthritis Rheum. 1997;26(suppl 1):21-27.
20. Hubbard R, Geis GS, Woods E, et al. Efficacy, tolerability and safety of celecoxib, a specific COX-2 inhibitor, in osteoarthritis. Arthritis Rheum. 1998;41(suppl):5196. (Abstr.)
21. Griffin MR, Piper JM, Daugherty JR, et al. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med. 1991;114: 257-263.
22. rd ed. Montvale, NJ: Medical Economics Co., 1999.
23. Cook ME, Wallin JD, Thakur VD, et al. Comparative effects of nabumetone, sulindac, and ibuprofen on renal function. J Rheumatol. 1995, 24: 1137-1144.
24. Geiss GS, Stead H, Morant S, et al. Efficacy and safety of celecoxib, a specific COX-2 inhibitor, in patients with rheumatoid arthritis. Arthritis Rheum. 1998;41(suppl):S316 (Abstr.)
25. Fenner H. Differentiating among NSAIDs by pharmacokinetic and pharmacodynamic profiles. Semin Arthritis Rheum. 1997;26:28-33.